What is the role of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) in the scenario of new drugs for Multiple Myeloma (MM)
Keyword(s):
Patients with multiple myeloma (MM) in clinical conditions to be referred to autologous hematopoietic stem cell transplantation (AHSCT) generally start therapy with an induction chemotherapy followed by high-dose alkylating and AHSCT. The ideal regimen and the number of pre-AHSCT induction is still a controversial subject, however, opting for at least three to four cycles of chemotherapy including a drug with immunomodulatory action, a proteasome inhibitor, with a corticosteroid, are advised as the first line before AHSCT.
2016 ◽
Vol 22
(8)
◽
pp. 1391-1396
◽
2006 ◽
Vol 12
(2)
◽
pp. 97
2005 ◽
Vol 11
(2)
◽
pp. 87
◽
2014 ◽
Vol 20
(2)
◽
pp. S46-S47
2007 ◽
Vol 85
(5)
◽
pp. 408-414
◽